Objective: To assess long-term efficacy and safety of salsalate to improve glycemia in persons with diabetes risk, who are overweight with statin-treated, stable coronary heart disease. /μL, P<0.001) and increased adiponectin (mean difference 1.8 μg/mL, 95%CI: 0.9 to 2.6 μg/mL, P<0.001) and albuminurea (16.7 μg/mg, 95%CI: 6.4 to 27.1 μg/mg, P<0.001) compared to placebo, consistent with previous results for patients with type 2 diabetes taking salsalate for shorter times.
, fasting glucose 92.8AE11.0 mg/dL, and HbA1c 5.8AE0.3%. Reductions in mean fasting glucose -5.70 mg/dL (95%CI: -7.44 to -3.97 mg/dL, P<0.001), HbA1c -0.11% (95%CI: -0.210 to -0.002%, P=0.046) and glycated serum protein -81.8 μg/mL (95%CI: -93.7 to -69.9 μg/mL, P<0.001) were demonstrated in salsalate compared to placebo-assigned groups over 30 months. Reductions in fasting glucose and glycated serum protein were greater with salsalate compared to placebo in participants with prediabetes compared to a normoglycemic sub-group (P interaction =0.018). Salsalate lowered total white blood cell counts (mean difference -0.7x10 3 /μL, 95%CI: -1.0 to -0.4x10 3 /μL, P<0.001) and increased adiponectin (mean difference 1.8 μg/mL, 95%CI: 0.9 to 2.6 μg/mL, P<0.001) and albuminurea (16.7 μg/mg, 95%CI: 6.4 to 27.1 μg/mg, P<0.001) compared to placebo, consistent with previous results for patients with type 2 diabetes taking salsalate for shorter times.
Conclusions: Salsalate improves glycemia in obese persons at increased risk for diabetes, and hence may decrease risk of incident type 2 diabetes. Salsalate may inform new therapeutic approaches for diabetes prevention, but renal safety may limit clinical utility. (Table S1 , Appendix S1). Of the 192 trial participants without diabetes, 147 (77%) completed the study. The proportion who completed the trial tended to be lower in salsalate compared with placebo (P = .088), the reasons are provided in Figure S1 . Expected visits were 99% completed. No participants were unmasked during the trial.
| Glycaemia
Fasting glucose decreased 6% in salsalate compared with placebo groups (P < .001) over 30 months. Fasting glucose declined 
| Other measures of efficacy and safety
Adiponectin increased 25% more with salsalate compared with placebo (P < .001). hsCRP decreased in both groups, with no difference in change between groups (P = .885; Table S2 , Appendix S1). Total white blood cell (WBC) count decreased in salsalate by 11% compared with placebo (P < .001), whereas haematocrit increased 1.6% (P = .012).
Triglycerides trended to be 10% lower in salsalate compared with placebo (P = .057). There was no difference in change for total cholesterol, low-density lipoprotein (LDL)-cholesterol or high-density lipoprotein (HDL)-cholesterol (P = .169, P = .111 and P = .175, respectively) between groups.
An increased urine albumin-to-creatinine ratio of 16.7 mcg/mg (95% CI: 6.4-27.1, P < .001) was seen in salsalate compared with placebo. Change in estimated glomerular filtration rate was similar between treatment groups (P = .278), with a decline in both (−3.7% vs −2.6%, salsalate vs placebo, respectively).
| Adverse events
No episodes of symptomatic hypoglycaemia were reported in either group. Serious adverse events were balanced between groups (Table S3 , Appendix S1). More salsalate-treated patients reported new onset or worsening of tinnitus compared with placebo (35% vs 16%, P = .005). Numerically more patients experienced atrial arrhythmias with salsalate than placebo (8% vs 2%, P = .103). Non-serious adverse events occurring in >5% of participants, with numerically more with salsalate, are provided (Table S4 , Appendix S1).
| DISCUSSION
We demonstrate that salsalate improves fasting glucose, HbA1c and GSP compared with placebo, and effects are sustained over 30 months. Our findings are consistent with previous reports showing that salsalate improves glycaemia (Table S5 , Appendix S1), and also provide the largest number of non-diabetic patients followed for the longest duration of time, providing new information on durability of glycaemic improvement and safety in a population at high risk of developing type 2 diabetes.
Fasting glucose lowering occurred within 6 weeks and was sustained. The percentage decrease in fasting glucose (−6%) is similar to most shorter-duration studies (Table S5 , Appendix S1). We also demonstrate a greater magnitude reduction in fasting glucose with salsalate in patients with prediabetes compared with those with normal glycaemia. Changes in fasting glucose and hence basal hepatic glucose production, even without an effect on post-prandial glucose concentrations (Table S5 , Appendix S1), may impact HbA1c. 7 Postprandial glycaemia was not assessed.
Although one might not anticipate HbA1c lowering within the non-diabetic range, an absolute 0.1% decrease in salsalate-compared with placebo-assigned participants was seen, from the normative mean baseline of 5.8%. In contrast, others report no changes in HbA1c over 12 weeks or have not reported on HbA1c change (Table S5 , Appendix S1). In context, a dipeptidyl peptidase-4 inhibitor (linagliptin) reduced HbA1c by 0.16% in a 2-year efficacy study of patients with type 2 diabetes and starting HbA1c of 7.7%. 8 Several mechanisms may explain glycaemic improvements observed with salsalate. 9 Salicylates exert anti-inflammatory effects through multiple cellular mechanisms, including effects to stimulate adenosine monophosphate-activated protein kinase, inhibition of NF-κB or transcription factors in addition to NF-κB, cellular kinases, mitochondrial dehydrogenases, or 11-hydroxysteroid dehydrogenase type 1 in adipose tissue. Relative contributions of these potential mechanisms in humans in vivo cannot be distinguished.
Anti-inflammatory effects are clinically manifest by lowered leukocyte counts, and increased adiponectin, consistent with prior reports (Table S5 , Appendix S1). Increased adiponectin may be an informative biomarker for reduced risk for type 2 diabetes and cardiovascular disease. 10, 11 The durability of these anti-inflammatory effects is consistent with the improved glycaemia, but does not establish causality.
While shorter studies have demonstrated lowered CRP in overweight persons, CRP reductions are not seen in other studies, and were not seen in this study (Table S5 , Appendix S1). Statins decrease CRP, and salsalate had no additional effect on CRP, whereas salsalate lowered WBC counts and statins did not. This suggests distinct mechanisms without interactions between the responsible pathways.
Total cholesterol, LDL-cholesterol and HDL-cholesterol did not differ between salsalate and placebo groups. Effects of salsalate on LDL-cholesterol are inconsistent, increasing in some studies and 
